BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 28603071)

  • 41. Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission.
    Larsen K; Spencer H; Mohan M; Bailey C; Hill K; Kottarathara M; Parikh R; Hoque S; Erra A; Mitma AA; Mathur P; Yarlagadda L; Gundarlapalli S; Ogunsesan Y; Hussain M; Thalambedu N; Sehti J; Al Hadidi S; Thanendrarajan S; Graziutti M; Zangari M; Barlogie B; van Rhee F; Tricot G; Schinke C
    J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329966
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
    Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
    Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.
    El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D
    Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma.
    Jagannath S; Vesole DH; Zhang M; Desikan KR; Copeland N; Jagannath M; Bracy D; Jones R; Crowley J; Tricot G; Barlogie B
    Bone Marrow Transplant; 1997 Sep; 20(6):445-50. PubMed ID: 9313876
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Autologous Stem Cell Transplantation in Patients With Multiple Myeloma: An Activity-based Costing Analysis, Comparing a Total Inpatient Model Versus an Early Discharge Model.
    Martino M; Console G; Russo L; Meliado' A; Meliambro N; Moscato T; Irrera G; Messina G; Pontari A; Morabito F
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):506-512. PubMed ID: 28647402
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A comparison of CD34+ cell selected and unselected autologous peripheral blood stem cell transplantation for multiple myeloma: a case controlled analysis.
    Gandhi M; Jestice H; Scott M; Bloxham D; Bass G; Craig J; Marcus R
    Bone Marrow Transplant; 1999 Aug; 24(4):369-75. PubMed ID: 10467325
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation.
    El-Jawahri A; Chen YB; Brazauskas R; He N; Lee SJ; Knight JM; Majhail N; Buchbinder D; Schears RM; Wirk BM; Wood WA; Ahmed I; Aljurf M; Szer J; Beattie SM; Battiwalla M; Dandoy C; Diaz MA; D'Souza A; Freytes CO; Gajewski J; Gergis U; Hashmi SK; Jakubowski A; Kamble RT; Kindwall-Keller T; Lazarus HM; Malone AK; Marks DI; Meehan K; Savani BN; Olsson RF; Rizzieri D; Steinberg A; Speckhart D; Szwajcer D; Schoemans H; Seo S; Ustun C; Atsuta Y; Dalal J; Sales-Bonfim C; Khera N; Hahn T; Saber W
    Cancer; 2017 May; 123(10):1828-1838. PubMed ID: 28102896
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
    Lorenz EC; Gertz MA; Fervenza FC; Dispenzieri A; Lacy MQ; Hayman SR; Gastineau DA; Leung N
    Nephrol Dial Transplant; 2008 Jun; 23(6):2052-7. PubMed ID: 18178602
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mortality patterns among recipients of autologous hematopoietic stem cell transplantation for lymphoma and myeloma in the past three decades.
    Bhatt VR; Loberiza FR; Jing H; Bociek RG; Bierman PJ; Maness LJ; Vose JM; Armitage JO; Akhtari M
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):409-415.e1. PubMed ID: 25816932
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multicenter validation study of the Kanto Study Group for Cell Therapy.
    Nakaya A; Mori T; Tanaka M; Tomita N; Nakaseko C; Yano S; Fujisawa S; Sakamaki H; Aotsuka N; Yokota A; Kanda Y; Sakura T; Nanya Y; Saitoh T; Kanamori H; Takahashi S; Okamoto S
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1553-9. PubMed ID: 25034961
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life.
    Joseph NS; Gupta VA; Wyman S; Graiser M; Kaufman JL; Almaula D; Andrews J; Hofmeister C; Dhodapkar M; Heffner LT; Lonial S; Nooka AK
    Transplant Cell Ther; 2022 Feb; 28(2):75.e1-75.e7. PubMed ID: 34626863
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation.
    Sorror M; Storer B; Sandmaier BM; Maloney DG; Chauncey TR; Langston A; Maziarz RT; Pulsipher M; McSweeney PA; Storb R
    Cancer; 2008 May; 112(9):1992-2001. PubMed ID: 18311781
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting.
    Lisenko K; Sauer S; Bruckner T; Egerer G; Goldschmidt H; Hillengass J; Schmier JW; Shah S; Witzens-Harig M; Ho AD; Wuchter P
    BMC Cancer; 2017 Feb; 17(1):151. PubMed ID: 28228122
    [TBL] [Abstract][Full Text] [Related]  

  • 56. IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.
    Wechalekar A; Amato D; Chen C; Keith Stewart A; Reece D
    Ann Hematol; 2005 Feb; 84(2):115-7. PubMed ID: 15503021
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acute kidney injury in multiple myeloma patients undergoing autologous hematopoietic stem cell transplant: a cohort study.
    Rodrigues N; Costa C; Branco C; Martins C; Lopes JA
    J Nephrol; 2024 Mar; 37(2):419-428. PubMed ID: 38019417
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
    Cook G; Ashcroft AJ; Cairns DA; Williams CD; Brown JM; Cavenagh JD; Snowden JA; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Chown S; Heartin E; O'Connor S; Drayson MT; Hockaday A; Morris TC;
    Lancet Haematol; 2016 Jul; 3(7):e340-51. PubMed ID: 27374467
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents.
    Vaxman I; Visram A; Kumar S; Dispenzieri A; Buadi F; Dingli D; Lacy M; Muchtar E; Kapoor P; Hogan W; Hayman S; Leung N; Gonsalves W; Kourelis T; Warsame R; Berger T; Gertz MA
    Bone Marrow Transplant; 2021 May; 56(5):1144-1150. PubMed ID: 33273658
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival.
    Dhakal B; D'Souza A; Martens M; Kapke J; Harrington AM; Pasquini M; Saber W; Drobyski WR; Zhang MJ; Hamadani M; Hari PN
    Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):379-86. PubMed ID: 27160644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.